Streetbeat News

Revenues

INCY

In the past three months, 10 analysts have provided varied opinions on Incyte (NASDAQ:INCY), with recent ratings showing a mix of bullish and indifferent stances. The average 12-month price target for Incyte is now $70.8, down 1.21% from the previous $71.67. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on Incyte's market performance and future potential. Incyte, known for its small-molecule drugs including Jakafi and Opzelura, has shown a revenue growth rate of 9.35% as of December 31, 2023, but struggles with below-industry averages in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 5:01 pm

ALHC

Four analysts have recently updated their ratings on Alignment Healthcare (NASDAQ:ALHC), showing a mix of bullish and bearish sentiments. The average 12-month price target is now $7.00, down 34.4% from previous estimates, with individual targets ranging from $4.50 to $9.00. Analysts from Stifel, Piper Sandler, Barclays, and UBS have adjusted their price targets and ratings due to changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown impressive revenue growth of 28.63% as of December 31, 2023, but faces challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 5:00 pm

PRFT

Over the last three months, 4 analysts have provided diverse opinions on Perficient (NASDAQ:PRFT), with recent evaluations showing a mix of neutral and somewhat bullish stances. The average 12-month price target for PRFT has slightly increased to $69.5. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to Perficient's market dynamics and performance. Despite a revenue decline of -5.08% over the past 3 months, Perficient's financials show strong net margin and ROA, but a lower ROE and market capitalization compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 5:00 pm

GM

TSLA

General Motors (NYSE:GM) exceeded Q1 2024 expectations with a 7.6% revenue increase to $43.01 billion and a 26% net income rise to $2.95 billion, surpassing LSEG estimates. North America led with a 7.4% earnings increase to $3.84 billion. Despite losses in China and other markets, GM raised its 2024 guidance, including adjusted EBIT, EPS, and cash flow forecasts. GM's EV production remains on target, aiming for profitability in North America's EV sector in H2 2024. Tesla (NASDAQ:TSLA) reported its first YoY global sales drop and anticipates slower growth, highlighting the competitive EV landscape.

Portfolio Pulse from Upwallstreet

April 23, 2024 | 4:50 pm

MEDP

Medpace Holdings (NASDAQ:MEDP) has been evaluated by 5 analysts over the last three months, showing a diverse range of opinions from bullish to bearish. The average 12-month price target for MEDP has been raised to $437.00, indicating a 26.12% increase from the previous target. Analysts from firms like Jefferies, Deutsche Bank, UBS, and Baird have updated their ratings and price targets, reflecting positive sentiment towards the company's performance and market position. Medpace, a contract research organization, has shown strong financials with significant revenue growth, high net margin, and solid returns on equity and assets, alongside prudent debt management.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:01 pm

FIGS

In the past three months, FIGS (NYSE:FIGS) has been analyzed by 6 analysts, showing a range of sentiments from bullish to bearish. The average 12-month price target for FIGS is now $5.93, down 22.18% from the previous target, with a high estimate of $11.00 and a low of $4.25. Analysts have adjusted their ratings and price targets, reflecting a cautious outlook on the company's performance. Despite a lower market capitalization and challenges in maximizing ROE, FIGS has shown impressive revenue growth and net margin, outperforming industry averages in the Consumer Discretionary sector.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:00 pm

GNRC

Generac Hldgs (NYSE:GNRC) received mixed analyst ratings with a shift towards a more neutral stance in the last quarter. Analysts updated their price targets, reflecting a positive outlook with an average target of $135.0, marking a 6.44% increase from the previous target. The company's financial performance shows strong net margin and ROE but faces challenges with a high debt-to-equity ratio and lower revenue growth compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:00 pm

BLBD

Blue Bird (NASDAQ:BLBD) received mixed analyst ratings with 4 bullish and 1 somewhat bullish out of 5 recent ratings. Analysts updated their price targets, leading to an average target of $39.6, marking a 38.12% increase from the previous $28.67 average. The company's financials show positive trends, with significant revenue growth, high net margin, ROE, and ROA, despite a high debt-to-equity ratio. Blue Bird is a bus manufacturing company with a majority of sales in the U.S.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:00 pm

BTCUSD

Creditors of the defunct Mt. Gox crypto exchange have received updates on their claims, including the number of Bitcoin (BTC) they will receive and, in some cases, repayment dates. This development marks a significant step forward in the long-standing issue since Mt. Gox's bankruptcy in 2014. The distribution of a $9.2 billion Bitcoin hoard by Mt. Gox could potentially impact Bitcoin's price due to the possibility of a large-scale sell-off by creditors.

Portfolio Pulse from Murtuza Merchant

April 23, 2024 | 3:56 pm

XMTR

Analysts have recently updated their ratings and price targets for Xometry (NASDAQ:XMTR), showing a mix of opinions. The average 12-month price target is now $25.5, down from $35.33, reflecting a 27.82% decline. Analysts from JMP Securities, UBS, RBC Capital, and Goldman Sachs have adjusted their ratings and price targets, indicating a cautious outlook based on Xometry's market performance, revenue growth, and financial metrics. Xometry's revenue growth outpaces industry averages, but profitability and asset utilization lag behind.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 3:01 pm